In supplemental analyses, we observed an association between SNAP groups defined using CSF tau levels and PGRS for AD, suggesting that while APOE does not appear related to SNAP, some of the genetic risk associated with clinical AD is relevant to tau even in the absence of amyloidosis (see Table K in S1 Supplemental Materials). This evidence concerns the gene MAPT and Alzheimer disease.